Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
Q Wu, W Qian, X Sun, S Jiang - Journal of hematology & oncology, 2022 - Springer
Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
J Gong, A Chehrazi-Raffle, S Reddi… - Journal for immunotherapy …, 2018 - Springer
Early preclinical evidence provided the rationale for programmed cell death 1 (PD-1) and
programmed death ligand 1 (PD-L1) blockade as a potential form of cancer immunotherapy …
programmed death ligand 1 (PD-L1) blockade as a potential form of cancer immunotherapy …
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial
MR Patel, J Ellerton, JR Infante, M Agrawal… - The Lancet …, 2018 - thelancet.com
Background The approval of anti-programmed death ligand 1 (PD-L1) and anti-programmed
death 1 agents has expanded treatment options for patients with locally advanced or …
death 1 agents has expanded treatment options for patients with locally advanced or …
Targeting programmed cell death-1 (PD-1) and ligand (PD-L1): a new era in cancer active immunotherapy
Improved understanding of the immune system and its role in cancer development and
progression has led to impressive advances in the field of cancer immunotherapy over the …
progression has led to impressive advances in the field of cancer immunotherapy over the …
Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination
J Gong, TQ Le, E Massarelli, AE Hendifar… - … for immunotherapy of …, 2018 - Springer
Several inhibitors of programmed cell death-1 (PD-1) and programmed death ligand-1 (PD-
L1) have been approved as a form of immunotherapy for multiple cancers. Ionizing radiation …
L1) have been approved as a form of immunotherapy for multiple cancers. Ionizing radiation …
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy …
Background Few treatments with a distinct mechanism of action are available for patients
with platinum-refractory advanced or metastatic urothelial carcinoma. We assessed the …
with platinum-refractory advanced or metastatic urothelial carcinoma. We assessed the …
Biomarkers for immunotherapy in bladder cancer: a moving target
Abstract Treatment options for metastatic urothelial carcinoma (mUC) remained relative
unchanged over the last 30 years with combination chemotherapy as the mainstay of …
unchanged over the last 30 years with combination chemotherapy as the mainstay of …
Durvalumab: first global approval
YY Syed - Drugs, 2017 - Springer
Abstract Intravenous durvalumab (Imfinzi™; AstraZeneca) is a fully human monoclonal
antibody that blocks programmed cell death ligand-1 binding to its receptors (PD-1 and …
antibody that blocks programmed cell death ligand-1 binding to its receptors (PD-1 and …
Recent advances in the clinical development of immune checkpoint blockade therapy
A Ghahremanloo, A Soltani, SMS Modaresi… - Cellular Oncology, 2019 - Springer
Background The discovery of immune checkpoint proteins and the mechanisms by which
cancer cells utilize them to evade the immune system has transformed our approach to …
cancer cells utilize them to evade the immune system has transformed our approach to …
Anti-VEGF/VEGFR2 monoclonal antibodies and their combinations with PD-1/PD-L1 inhibitors in clinic
F Gao, C Yang - Current cancer drug targets, 2020 - ingentaconnect.com
The vascular endothelial growth factor (VEGF)/VEGF receptor 2 (VEGFR2) signaling
pathway is one of the most important pathways responsible for tumor angiogenesis …
pathway is one of the most important pathways responsible for tumor angiogenesis …